Abstract
rotoxicity. RESULTS: Pretreatment with hASC but not the post-treatment, significantly decreased the rate of preterm birth (p 0.01) by 21%. Pretreatment was associated with increase in IL-10 in MS (p 0.05) and IL-4 in AF (p 0.05); decrease in IL1 cytokine expression in fetal and neonatal brains, and fetal neurotoxicity (p 0.05). CONCLUSION: Maternally administered adipose derived mesenchymal stem cells appear to modulate maternal and fetal response to intrauterine inflammation in a murine model. While further research is needed, this study is the first to demonstrate that autologous hASC harvested from women with history of preterm birth may serve as a cell therapy “vaccine” in their future pregnancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
